Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding FDA-approved LUMRYZ for narcolepsy to its commercial portfolio.
The $2.3 billion cash-and-debt deal expands Alkermes’ presence in sleep medicine, strengthens its late-stage pipeline, enhances commercial capabilities, and is expected to be accretive in 2026.